Skip to content

Ketamine for depression: all studies

Page 102 of 154: studies 1,011 to 1,020 of 1,534, newest first. Back to the ketamine for depression overview

Research

A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation

International Journal of Neuropsychopharmacology March 26, 2023 T. Su, Cheng-Ta Li, Wei-Chen Lin et al. 48 citations

Abstract Background The benefits of low-dose ketamine for patients with treatment-resistant depression (TRD) and prominent suicidal ideation require further investigation. The effects of treatment refractoriness, the duration of the current depressive episode, and the number of prior antidepressant failures on ketamine efficacy also require clarification. Methods We recruited 84 outpatients...

Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray

Psychiatry Research March 15, 2023 Ibrahim Turkoz, J. Craig Nelson, Samuel T. Wilkinson et al. 19 citations

This exploratory post hoc analysis of two pooled 4-week, phase 3, double-blind, placebo- and active-controlled studies that compared esketamine nasal spray plus a newly initiated oral antidepressant (ESK+AD; n = 310) with a newly initiated oral AD plus placebo nasal spray (AD+PBO; n = 208) in patients with treatment-resistant depression (TRD) examined baseline patient demographic and...

Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis.

Neuropsychiatric Disease and Treatment March 14, 2023 Cheng-Chuan Chen, Na Zhou, Na Hu et al.

Purpose: Suicide is a major public health concern with currently no validated and efficacious treatments approved. Preliminary evidence suggests that intravenous ketamine has rapid and sustained antidepressant effects, making it a candidate with therapeutic potential for depressed patients at risk for suicide. We conducted a meta-analysis to evaluate the efficacy of ketamine and esketamine in...

Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial.

Trends in Psychiatry and Psychotherapy March 7, 2023 Ana Teresa Caliman-Fontes, Gustavo C Leal, Fernanda S Correia-Melo et al.

Objectives: Evidence suggests that ketamine's influence on brain-derived neurotrophic factor (BDNF) might be involved in its mechanism of rapid antidepressant action. We aimed to evaluate the differential impact of ketamine and esketamine on serum BDNF levels and its association with response patterns in treatment-resistant depression (TRD). Methods: Participants (n = 53) are from a randomized,...

Inhibition of Microglial GSK3β Activity Is Common to Different Kinds of Antidepressants: A Proposal for an In Vitro Screen to Detect Novel Antidepressant Principles.

Biomedicines March 7, 2023 Hans O. Kalkman 16 citations

Depression is a major public health concern. Unfortunately, the present antidepressants often are insufficiently effective, whilst the discovery of more effective antidepressants has been extremely sluggish. The objective of this review was to combine the literature on depression with the pharmacology of antidepressant compounds, in order to formulate a conceivable pathophysiological process,...

Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder.

Psychiatry Research March 5, 2023 Kevork Danayan, Noah Chisamore, Nelson B Rodrigues et al. 36 citations

Borderline personality disorder (BPD) has high rates of comorbidity with mood disorders, including treatment-resistant depression (TRD). Comorbidity of BPD with depression is associated with poorer response to antidepressants. Intravenous ketamine is a novel treatment for TRD that has not been specifically evaluated in patients with comorbid BPD. In this retrospective analysis of data collected...

TOLERANCE AND ACCEPTABILITY OF INTRAVENOUS KETAMINE THERAPY FOR TREATMENT RESISTANT DEPRESSION: A MIXED METHODS ASSESSMENT

Journal of Pakistan Psychiatric Society March 3, 2023 Sawera Mansoor, Khalid Hayat Khan, Manzoor Ahmed Faridi 3 citations

Objectives: This study was conducted to evaluate the response of treatment resistant depression to IV ketamine therapy protocol and explore the perspectives of patients regarding the acceptability of this treatment modality. Study Design: Mixed methods assessment including Quasi experimental design and Qualitative interviews. Place and Duration of Study: The study was conducted at Department of...

Cortical inhibition function is associated with baseline suicidal symptoms and post-ketamine suicidal symptom reduction among patients with treatment-resistant depression and strong suicidal ideation.

Journal of Psychiatric Research March 1, 2023 Mu-Hong Chen, T. Su, Li-Fen Chen et al.

BACKGROUND Whether cortical excitation and inhibition functions differ between patients with treatment-resistant depression (TRD) and strong suicidal ideation (SI) and healthy subjects and whether 0.5 mg/kg ketamine infusion can modulate cortical excitation and inhibition functions among patients with TRD-SI remain unclear. METHODS A total of 29 patients with TRD-SI and 35 age- and sex-matched...

Adjunctive short- and long-term combination treatment of esketamine and VNS in difficult to treat depression (DTD)

European Psychiatry March 1, 2023 Erhan Kavakbasi, Bernhard T Baune

IntroductionNMDA-Receptor antagonists have rapid antidepressant and antisuicidal properties. However, the antidepressant effect is short lasting raising the question of best maintenance strategy, which is unanswered so far. Invasive vagus nerve stimulation (VNS) as a treatment option for refractory and chronic major depression was shown to reduce the need of maintenance treatment sessions in...

Effect of pre-administration of esketamine intraoperatively on postpartum depression after cesarean section: A randomized, double-blinded controlled trial.

Medicine March 1, 2023 Wei Wang, Bin Ling, Qian Chen et al.

Background: To evaluate the effect of pre-administration of esketamine intraoperatively on the occurrence of postpartum depression after cesarean section under combined spinal-epidural anesthesia. Methods: A total of 120 women aged 24 to 36 years undergoing cesarean section by spinal-epidural anesthesia with American Society of Anesthesiologists physical status II were enrolled. According to...

DOI: 10.1097/md.0000000000033086 (opens in new tab) Full text (opens in new tab) Ketamine Humans Depression, postpartum Anesthesia, epidural +4